Velcade, Revlimid, and Dexamethasone Combination Remains Standard-of-Care First-Line Therapy for Patients with Multiple Myeloma - Conquer: the journey informed
IRd Vs Rd Maintenance after Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma Pts: Results of the Spanish GEM2014MAIN Trial
Lenalidomide in Combination With Dexamethasone in Newly Diagnosed Multiple Myeloma - The ASCO Post
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial - The Lancet Oncology
547-Lenalidomide and dexamethasone oral | eviQ
Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan | SpringerLink
Revlimid/ Dexamethasone : r/multiplemyeloma
A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. - Abstract - Europe PMC
Velcade/Revlimid/Dexamethasone New Standard for Newly Diagnosed Multiple Myeloma - CancerConnect
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma | NEJM
Relapsed Multiple Myeloma Treatment Results | KYPROLIS® (carfilzomib)
DRd Trial Design & Efficacy | REVLIMID® (lenalidomide)
Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone - ScienceDirect
Cost-effectiveness of lenalidomide in combination with dexamethasone compared to bortezomib in combination with dexamethasone for the second-line treatment of multiple myeloma in Chile - Medwave
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement | Leukemia
No Survival Benefit With All-Oral Regimen for Relapsed/Refractory Myeloma | MedPage Today
The benefits of lenalidomide and dexamethasone for multiple myeloma - YouTube
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial | Blood Cancer Journal
Aftermath of Revlimid of primary benefit multiple myeloma
Revlimid/ Dexamethasone : r/multiplemyeloma
Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial - The Lancet Haematology
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial - The Lancet Oncology
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial - The Lancet
REVLIMID® (lenalidomide) - Official Patient Website
ADD Velcade, Revlimid, and dex (VRd) | Int Myeloma Fn
Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma - Lund - 2018 - Cancer Medicine - Wiley Online Library
